<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Computational investigation of single herbal drugs in Ayurveda for diabetes and obesity using knowledge graph and network pharmacology - Health AI Hub</title>
    <meta name="description" content="This paper presents an integrated computational pipeline leveraging knowledge graphs, pathway analysis, and network pharmacology to elucidate the multi-target m">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Computational investigation of single herbal drugs in Ayurveda for diabetes and obesity using knowledge graph and network pharmacology</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2601.21643v1" target="_blank">2601.21643v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2026-01-29
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Priyotosh Sil, Rahul Tiwari, Vasavi Garisetti, Shanmuga Priya Baskaran, Fenita Hephzibah Dhanaseelan, Smita Srivastava, Areejit Samal
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.MN, q-bio.SC
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2601.21643v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2601.21643v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper presents an integrated computational pipeline leveraging knowledge graphs, pathway analysis, and network pharmacology to elucidate the multi-target mechanisms of Ayurvedic Single Herbal Drugs (SHDs) for type 2 diabetes and obesity. It successfully identified key disease-relevant targets, synergistic phytochemical interactions, and putative lead compounds, thereby providing a scientific basis for the multi-faceted action of these traditional medicines.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research provides a robust, systematic approach to understand the complex, multi-target mechanisms of traditional Ayurvedic medicines for prevalent metabolic diseases. By identifying specific molecular targets and synergistic phytochemical combinations, it can accelerate the discovery of novel, multi-modal therapeutic strategies that address the multi-factorial nature of diabetes and obesity, potentially leading to more effective and holistic treatments.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper applies AI/computational methods such as knowledge graphs (Neo4j-based), network pharmacology, and molecular docking to analyze complex biological and chemical data. Specifically, it uses a knowledge graph for SHD-disease intersection analysis and target prioritization, network pharmacology for understanding protein-protein interactions and drug mechanisms, and molecular docking for identifying lead phytochemicals. These applications directly contribute to drug discovery, target identification, and understanding the molecular basis of disease and therapeutic intervention for diabetes and obesity.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Developed an integrated computational pipeline combining knowledge graphs, pathway analysis, and network pharmacology for analyzing SHD mechanisms.</li>
                    
                    <li>Curated 11 Ayurvedic SHDs and 188 phytochemicals for diabetes/obesity, filtered for drug-likeness and bioavailability.</li>
                    
                    <li>Prioritized key disease-relevant targets (PTPN1, GLP1R, DPP4) through SHD-disease intersection analysis embedded in a Neo4j knowledge graph.</li>
                    
                    <li>Identified PPARG as a central regulatory target through network pharmacology based protein-protein interaction analysis.</li>
                    
                    <li>Demonstrated the multi-target action of SHDs as 'phytochemical cocktails,' aligning their mechanisms with clinically synergistic FDA-approved drug combinations.</li>
                    
                    <li>Discovered structurally dissimilar and target-wise distinct phytochemical pairs within SHDs that exhibit complementary and potentially synergistic interactions on disease pathways.</li>
                    
                    <li>Identified putative lead phytochemicals for selected druggable targets through molecular docking analysis.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study involved a multi-faceted computational pipeline: 1) Curation of SHDs from Ayurvedic Pharmacopoeia and phytochemicals from IMPPAT, followed by drug-likeness/bioavailability filtering. 2) Curation of molecular targets for phytochemicals, disease-associated genes, and FDA-approved drug targets from various databases. 3) Pathway enrichment analysis to identify functional overlaps. 4) Construction of a Neo4j-based knowledge graph for SHD-disease intersection analysis. 5) Network pharmacology (protein-protein interaction) analysis. 6) A quantitative framework to identify synergistic phytochemical pairs. 7) Molecular docking simulations to identify lead phytochemicals against selected targets.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The study found significant functional overlap between SHD-associated and disease-associated pathways. Key disease-relevant targets such as PTPN1, GLP1R, and DPP4 were prioritized. PPARG was identified as a central regulator via network pharmacology. The research elucidated that SHDs act as 'phytochemical cocktails' with multi-target mechanisms, which align with synergistic FDA-approved drug combinations. It also identified specific phytochemical pairs within SHDs that, despite structural and target dissimilarity, show potential synergistic or complementary actions on disease pathways. Molecular docking revealed putative lead phytochemicals for specific druggable targets.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This computational framework offers a scientific rationale for the efficacy of traditional Ayurvedic SHDs in managing diabetes and obesity. It can guide the rational design of new multi-target therapies, potentially leading to the development of novel drugs or phytomedicines that address multiple aspects of metabolic diseases more effectively than single-target agents. The identification of lead phytochemicals and synergistic pairs provides concrete starting points for future drug development and clinical investigations.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations. However, as a purely computational study, its findings are *in silico* predictions that require rigorous experimental validation (in vitro and in vivo) to confirm the predicted molecular targets, mechanisms, and therapeutic efficacy. The results are also dependent on the completeness and accuracy of the underlying biological and chemical databases used for data curation.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Implied future directions include experimental validation of the identified key targets, synergistic phytochemical pairs, and putative lead phytochemicals through *in vitro* and *in vivo* studies. Further investigation into the pharmacokinetics and pharmacodynamics of the identified multi-phytochemical combinations is also warranted to translate these computational insights into clinically viable therapeutic strategies.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Endocrinology</span>
                    
                    <span class="tag">Metabolism</span>
                    
                    <span class="tag">Integrative Medicine</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Computational Biology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Ayurveda</span>
                    
                    <span class="tag tag-keyword">Single Herbal Drugs</span>
                    
                    <span class="tag tag-keyword">Diabetes</span>
                    
                    <span class="tag tag-keyword">Obesity</span>
                    
                    <span class="tag tag-keyword">Knowledge Graph</span>
                    
                    <span class="tag tag-keyword">Network Pharmacology</span>
                    
                    <span class="tag tag-keyword">Multi-target</span>
                    
                    <span class="tag tag-keyword">Phytochemicals</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Metabolic Diseases</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Metabolic diseases such as type 2 diabetes and obesity represent a rapidly escalating global health burden, yet current therapeutic strategies largely target isolated symptoms or single molecular pathways. To this end, we developed an integrated computational pipeline leveraging knowledge graph, pathway analysis and network pharmacology to elucidate the multi-target mechanisms of Ayurvedic Single Herbal Drugs (SHDs). SHDs associated with diabetes and obesity were curated from the Ayurvedic Pharmacopoeia of India, followed by phytochemical identification using IMPPAT database, yielding a shortlist of 11 SHDs and their 188 phytochemicals after drug-likeness and bioavailability filtering. Subsequently, molecular targets of the phytochemicals in SHDs, disease-associated genes and therapeutic targets of FDA-approved drugs, were curated via integration of data from several databases. Pathway enrichment analysis revealed significant functional overlap between SHD-associated and disease-associated pathways. All curated data were embedded into a Neo4j-based knowledge graph, enabling SHD-disease intersection analysis that prioritized key disease-relevant targets, including PTPN1, GLP1R, and DPP4. Also, the SHD-Target-FDA-approved drug profile elucidated the molecular and mechanistic aspects of the SHDs as a phytochemical cocktail, and is in alignment with the clinically studied synergistic FDA-approved drug combinations. Network pharmacology based protein-protein interaction analysis identified PPARG as another central regulator. Using a quantitative framework, we identified phytochemical pairs within SHDs, which were structurally dissimilar and target-wise distinct, yet acted on shared or different disease-associated pathways, indicating complementary and potentially synergistic interactions. Molecular docking analysis of two selected druggable targets identified putative lead phytochemicals.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>58 pages of main text with 8 figures and 2 tables, 15 supplementary figures and 16 supplementary tables appended to main text</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>